Fate Therapeutics (FATE) Competitors $1.24 -0.04 (-3.13%) Closing price 04:00 PM EasternExtended Trading$1.20 -0.03 (-2.82%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. PHAR, VALN, ORGO, CRMD, OPT, UPB, BCYC, IMTX, PRTA, and KURAShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Pharming Group (PHAR), Valneva (VALN), Organogenesis (ORGO), CorMedix (CRMD), Opthea (OPT), Upstream Bio (UPB), Bicycle Therapeutics (BCYC), Immatics (IMTX), Prothena (PRTA), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Pharming Group Valneva Organogenesis CorMedix Opthea Upstream Bio Bicycle Therapeutics Immatics Prothena Kura Oncology Fate Therapeutics (NASDAQ:FATE) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Which has more volatility & risk, FATE or PHAR? Fate Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Does the MarketBeat Community prefer FATE or PHAR? Fate Therapeutics received 457 more outperform votes than Pharming Group when rated by MarketBeat users. However, 67.65% of users gave Pharming Group an outperform vote while only 67.51% of users gave Fate Therapeutics an outperform vote. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48067.51% Underperform Votes23132.49% Pharming GroupOutperform Votes2367.65% Underperform Votes1132.35% Do insiders & institutionals hold more shares of FATE or PHAR? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate FATE or PHAR? Fate Therapeutics presently has a consensus price target of $5.43, suggesting a potential upside of 324.11%. Pharming Group has a consensus price target of $30.00, suggesting a potential upside of 242.08%. Given Fate Therapeutics' higher probable upside, equities research analysts plainly believe Fate Therapeutics is more favorable than Pharming Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FATE or PHAR more profitable? Pharming Group has a net margin of -6.09% compared to Fate Therapeutics' net margin of -1,325.43%. Pharming Group's return on equity of -7.65% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% Pharming Group -6.09%-7.65%-3.82% Which has preferable earnings and valuation, FATE or PHAR? Pharming Group has higher revenue and earnings than Fate Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M10.76-$160.93M-$1.64-0.78Pharming Group$297.20M2.01-$10.55M-$0.17-51.59 Does the media refer more to FATE or PHAR? In the previous week, Pharming Group had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 8 mentions for Pharming Group and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.80 beat Pharming Group's score of 0.75 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPharming Group beats Fate Therapeutics on 10 of the 18 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.69M$3.00B$5.56B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.7830.4222.5118.48Price / Sales10.76498.92395.68103.60Price / CashN/A168.6838.1834.62Price / Book0.343.206.774.25Net Income-$160.93M-$72.35M$3.22B$248.23M7 Day Performance-5.19%1.46%1.45%0.89%1 Month Performance69.07%8.79%3.97%3.53%1 Year Performance-68.70%-22.36%16.14%5.08% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.7548 of 5 stars$1.24-3.1%$5.43+337.8%-67.6%$142.11M$13.63M-0.75550Upcoming EarningsPHARPharming Group2.5184 of 5 stars$8.15+0.7%$30.00+268.1%-6.6%$554.45M$297.20M-31.35280Upcoming EarningsShort Interest ↓News CoveragePositive NewsVALNValneva2.5237 of 5 stars$6.63-2.4%$16.00+141.3%-14.9%$538.76M$169.58M-51.00700Upcoming EarningsShort Interest ↓ORGOOrganogenesis3.4236 of 5 stars$4.21-0.2%$5.50+30.6%+108.9%$533.95M$482.04M-70.17950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.5018 of 5 stars$8.14+6.1%$14.50+78.1%+74.9%$530.58M$43.47M-10.0530Upcoming EarningsPositive NewsOPTOpthea0.9092 of 5 stars$3.41+7.2%$1.33-60.9%-0.6%$524.84M$87,666.000.008News CoverageGap UpUPBUpstream BioN/A$9.71+10.6%$56.50+481.9%N/A$520.85M$2.37M0.0038News CoveragePositive NewsBCYCBicycle Therapeutics3.0381 of 5 stars$7.51+1.6%$29.14+288.1%-63.5%$519.71M$35.28M-2.28240Short Interest ↓Positive NewsIMTXImmatics2.0574 of 5 stars$4.24-0.5%$16.67+293.1%-49.6%$515.37M$155.84M-6.42260Positive NewsPRTAProthena3.4243 of 5 stars$9.30+1.1%$55.00+491.4%-54.8%$500.59M$135.16M-4.04130Upcoming EarningsNews CoverageKURAKura Oncology4.134 of 5 stars$6.18+4.7%$25.50+312.6%-66.6%$499.21M$53.88M-2.62130Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Pharming Group Alternatives Valneva Alternatives Organogenesis Alternatives CorMedix Alternatives Opthea Alternatives Upstream Bio Alternatives Bicycle Therapeutics Alternatives Immatics Alternatives Prothena Alternatives Kura Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts